There is a dire need for due innovative therapeutic modalities to improve outcomes of AD patients. In this study, we tested whether cannabidiol (CBD) improves outcomes in a translational model of familial AD and to investigate if CBD regulates interleukin (IL)-33 and triggering receptor expressed on myeloid cells 2 (TREM2), which are associated with improved cognitive function. CBD was administered to 5xFAD mice, which recapitulate early onset, familial AD. Behavioral tests and immunoassays were used to evaluate cognitive and motor outcomes. Our findings suggest that CBD treatment enhanced IL-33 and TREM2 expression, ameliorated the symptoms of AD, and retarded cognitive decline.
MontineTJ, BukhariSA, WhiteLR (2021) Cognitive impairment in older adults and therapeutic strategies. Pharmacol Rev73, 152–162.
5.
ZucchellaC, SinforianiE, TamburinS, FedericoA, MantovaniE, BerniniS, CasaleR, BartoloM (2018) The multidisciplinary approach to Alzheimer’s disease and dementia. A narrative review of non-pharmacological treatment. Front Neurol9, 1058–1080.
HaoF, FengY (2021) Cannabidiol (CBD) enhanced the hippocampal immune response and autophagy of APP/PS1 Alzheimer’s mice uncovered by RNA-seq. Life Sci264, 118624–118634.
8.
MulderJ, ZilberterM, PasquaréSJ, AlpárA, SchulteG, FerreiraSG, KöfalviA, Martín-MorenoAM, KeimpemaE, TanilaH, WatanabeM, MackieK, HortobágyiT, de CeballosML, HarkanyT (2011) Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease. Brain134, 1041–1060.
9.
PáezJA, CampilloNE (2019) Innovative therapeutic potential of cannabinoid receptors as targets in Alzheimer’s disease and less well-known diseases. Curr Med Chem26, 3300–3340.
10.
LiewFY, GirardJP, TurnquistHR (2016) Interleukin-33 in health and disease. Nat Rev Immunol16, 676–689.
11.
SaresellaM, MarventanoI, PianconeF, La RosaF, GalimbertiD, FenoglioC, ScarpiniE, ClericiM (2020) IL-33 and its decoy sST2 in patients with Alzheimer’s disease and mild cognitive impairment. J Neuroinflammation17, 174–184.
12.
LiangCS, SuKP, TsaiCL, LeeJT, ChuCS, YehTC, SuMW, LinGY, LinYK, ChuHT, TsaiCK, YangFC (2020) The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther12, 86–95.
13.
Abd Rachman IsnadiMF, ChinVK, Abd MajidR, LeeTY, Atmadini AbdullahM, Bello OmenesaR, Osamah IbraheemZ, BasirR (2018) Critical roles of IL-33/ST2 pathway in neurological disorders. Mediators Inflamm2018, 5346413–5346422.
14.
GratuzeM, LeynsCEG, HoltzmanDM (2018) New insights into the role of TREM2 in Alzheimer’s disease. Mol Neurodegener13, 66–82.
15.
LiuW, TasoO, WangR, BayramS, GrahamAC, Garcia-ReitboeckP, MallachA, AndrewsWD, PiersTM, BotiaJA, PocockJM, CummingsDM, HardyJ, EdwardsFA, SalihDA (2020) Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions. Hum Mol Genet29, 3224–3248.
